PDS Biotechnology (PDSB)
(Delayed Data from NSDQ)
$3.27 USD
+0.01 (0.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.27 USD
+0.01 (0.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
by Zacks Equity Research
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
by Zacks Equity Research
Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.
PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
by Zacks Equity Research
PDS Biotech's (PDSB) shares gain as it announces encouraging interim data from the VERSATILE-002 study for treating HPV16-positive cancer patients.
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
by Zacks Equity Research
PDS Biotech (PDSB) shares gain as it completes patient enrollment in the second arm of the VERSATILE-002 study for treating HPV16-positive cancer patients.
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
by Zacks Equity Research
A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.
How Much Upside is Left in PDS Biotechnology (PDSB)? Wall Street Analysts Think 265%
by Zacks Equity Research
The consensus price target hints at a 265.3% upside potential for PDS Biotechnology (PDSB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Company News for Jun 9, 2021
by Zacks Equity Research
Companies in the news are: MOMO, NAV, ASO, PDSB
Implied Volatility Surging for PDS Biotechnology (PDSB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to PDS Biotechnology (PDSB) stock based on the movements in the options market lately.
Implied Volatility Surging for PDS Biotechnology (PDSB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to PDS Biotechnology (PDSB) stock based on the movements in the options market lately.
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
PDS Biotechnology (PDSB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).